Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles D Houslay

Showing results (1-10 of 137) with videos related to

Pageof 14
Sort By:
The EMBO Journal|July 7, 2011
Arresting times for PTENMiles D Houslay
British Journal of Pharmacology|September 8, 2009
Disrupting specific PDZ domain-mediated interactions for therapeutic benefitMiles D Houslay
Molecular Pharmacology|June 17, 2005
The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic targetMiles D Houslay
Science'S STKE : Signal Transduction Knowledge Environment|August 24, 2006
A RSK(y) relationship with promiscuous PKAMiles D Houslay
Trends in Biochemical Sciences|October 30, 2009
Underpinning compartmentalised cAMP signalling through targeted cAMP breakdownMiles D Houslay
Cancer Cell|January 22, 2011
Hard times for oncogenic BRAF-expressing melanoma cellsMiles D Houslay
Science Signaling|April 16, 2009
Arrestin times for developing antipsychotics and beta-blockersMiles D Houslay
Cellular Signalling|December 22, 2014
Editorial: Reflections on being 'founding' Editor-in-Chief of Cellular SignallingMiles D Houslay
Trends in Cancer|July 26, 2017
Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and MetastasisMiles D Houslay
Autophagy|September 25, 2010
p62 (SQSTM1) forms part of a novel, reversible aggregate containing a specific conformer of the cAMP degrading phosphodiesterase, PDE4A4Miles D Houslay, Frank Christian
Pageof 14

Showing results (1-10 of 137) with videos related to

Sort By:
Pageof 14
The EMBO Journal|July 7, 2011
Arresting times for PTENMiles D Houslay
British Journal of Pharmacology|September 8, 2009
Disrupting specific PDZ domain-mediated interactions for therapeutic benefitMiles D Houslay
Molecular Pharmacology|June 17, 2005
The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic targetMiles D Houslay
Science'S STKE : Signal Transduction Knowledge Environment|August 24, 2006
A RSK(y) relationship with promiscuous PKAMiles D Houslay
Trends in Biochemical Sciences|October 30, 2009
Underpinning compartmentalised cAMP signalling through targeted cAMP breakdownMiles D Houslay
Cancer Cell|January 22, 2011
Hard times for oncogenic BRAF-expressing melanoma cellsMiles D Houslay
Science Signaling|April 16, 2009
Arrestin times for developing antipsychotics and beta-blockersMiles D Houslay
Cellular Signalling|December 22, 2014
Editorial: Reflections on being 'founding' Editor-in-Chief of Cellular SignallingMiles D Houslay
Trends in Cancer|July 26, 2017
Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and MetastasisMiles D Houslay
Autophagy|September 25, 2010
p62 (SQSTM1) forms part of a novel, reversible aggregate containing a specific conformer of the cAMP degrading phosphodiesterase, PDE4A4Miles D Houslay, Frank Christian
Pageof 14